There is mounting evidence to support a role for the c-myc protooncogene in tumour onset and progression. Myc directly modulates the basal transcription apparatus, as well as specific genes containing the consensus E-box element. Myc-responsive genes include those whose protein products regulate the cell cycle and cell death. Abnormal regulation of the c-myc gene by multiple mechanisms can result in phenotypic transformation, aberrant cell cycle control, and genomic instability. However, at present, only its gene amplification and overexpression have been described in breast cancer; neither gene rearrangement nor mutation have been described. No clear relationships have yet been described between c-myc amplification and overexpression of its mRNA nor protein in breast cancer nor in other tumour types where c-myc is commonly amplified (Varmus, 1984; Nass and Dickson, 1997; Dang, 1999) .
In breast cancer, the chromosome 8 region where the gene is localized has been identified as one of the three most commonly amplified regions of the genome (Courjal et al, 1997) ; this region also is commonly amplified in small cell lung carcinoma (Little et al, 1985) , leukaemia (Dalla-Farera et al, 1985) , and colon carcinoma (Alitalo et al, 1983) . C-myc has been considered to be the dominant oncogene in this region, driving the selection of this amplification in cancer. This supposition is based on the common expression of c-myc coupled with many demonstrations of its oncogenic properties in multiple types of cancer models. For example, in mouse transgenic models expression of the transgene under either the MMTV or WAP promoter, or by retroviral strategies, resulted in mammary tumours following multiple pregnancies (Leder et al, 1986; Edwards et al, 1988) .
These observations suggest that anomalous expression of c-myc may bring about a cascade of effects: altered cell cycle progression, genomic instability, and in some instances, tumorigenesis. In breast cancer, investigation of the relationship between the biological function and the clinical implications of c-myc gene amplification has produced inconsistent results. In an attempt to clarify the clinical relevance of c-myc amplification in breast cancer we performed a meta-analysis of the literature. To achieve this goal, our meta-analysis set out to address three specific questions: relevant papers were also used as means of identifying additional studies.
Inclusion and exclusion criteria
For inclusion in this meta-analysis, studies had to describe research determining the frequency of amplification of the c-myc gene in human breast tumours, and provide the number of amplified and non-amplified tumours. Studies that did not differentiate between gene amplification and other types of alteration (rearrangement and deletions) were excluded from the analysis. Multiple reports from the same study contributed only one estimate to the calculation of overall c-myc amplification frequency (Berns et al, 1992; Champeme et al, 1994; Scorilas et al, 1995) . However, subsequent reports containing new data on prognostic factors or survival were also incorporated into pooled analyses of the specific clinical end-points. Data from studies that used more than one method to determine the overall frequency of amplification were included separately in subgroup analyses of the individual methods (Zhou et al, 1989; Watson et al, 1993) . Consideration of methodologic aspects included the sources of tissue and amplification controls, specification of the positive threshold for gene amplification, and a description of the characteristics of the study population (Trock et al, 1997) .
For the association between c-myc amplification and a prognostic factor to be analysed, at least three studies were required to report data concerning that factor. Likewise, at least three studies containing hazard estimates or raw data to generate survival estimates were required for the association between survival and c-myc amplification to be examined. This number is arbitrary and was thought to represent the minimum amount of data that could provide an informative estimate of the magnitude of an association.
Methods of statistical analysis
For each study the proportion of breast tumours with amplified c-myc was extracted and 95% confidence intervals were calculated by standard methods (Fleiss, 1981) . For a pooled measure of c-myc gene amplification frequency, the proportions from each study were combined in a weighted average, using study sample size as weights. Homogeneity of the proportions across studies was determined using a chi-squared test for contingency tables. (Fleiss, 1981) .
The association of c-myc amplification with individual prognostic factors was expressed as a rate ratio (RR), i.e. the relative probability of c-myc amplification in tumours with the adverse prognostic factor compared to those without the adverse factor. Study-specific RRs were pooled across all studies with a MantelHaenszel approach (MH), using the procedure PROC FREQ in SAS (Statistical Analysis Systems Institute Inc, Cary, NC). The homogeneity of the RRs across the studies was determined using the method of Breslow and Day (1987) .
The association between c-myc amplification and either overall survival (OS) or disease-free survival (DFS) was derived as a weighted average of study-specific estimates of the hazard ratio (HR), using inverse variance weights (Kleinbaum et al, 1982) . This required the HR and its standard error (Tsuda et al, 1989; Berns et al, 1992; Borg et al, 1992) , or inclusion of sufficient raw data in the published report for us to perform a multivariable proportional hazards regression (Varley et al, 1987 ) (using PROC PHREG in SAS). For studies that did not provide HR estimates or the raw data (Yamashita et al, 1993; Lonn et al, 1995) , we derived estimates of the HRs by calculating the smallest HR that could be detected with power = 0.80 at the P-values actually observed, using standard power calculations for survival analysis (George and Desu, 1974) . The standard error of this derived HR estimate was obtained by dividing the log (HR) estimate by the square-root of the Wald chi-square statistic associated with the observed Pvalue. As an ad hoc check on the validity of this approach we used the same derivation in the three studies that did provide HRs. The derived HRs from these three studies were in most instances conservative, that is, they were generally smaller than those actually observed in the studies.
RESULTS

Results of citation search
Forty reports were initially identified by our search. Eleven studies that reported only data concerning over-expression of the c-myc protein, or that did not distinguish between amplification and other alterations of the c-myc gene were excluded. The analysis included 29 reports (representing 26 distinct studies) that met the inclusion criteria. Twenty-six of the 29 reports were included in the estimation of the overall proportion of c-myc-amplified tumors (Escot et al, 1986; Cline et al, 1987; Varley et al, 1987; Bonilla et al, 1988; Guerin et al, 1988; Adnane et al, 1989; Garcia et al, 1989; Tavassoli et al, 1989; Tsuda et al, 1989; Zhou et al, 1989; Brouillet et al, 1990; Meyers et al, 1990; Munzel et al, 1991; Berns et al, 1992b; Borg et al, 1992; Roux-Dosseto et al, 1992; Kreipe et al, 1993; Nagayama and Watatani, 1993; Ottestad et al, 1993; Scorilas et al, 1993; Watson et al, 1996; Yamashita et al, 1993; Bieche et al, 1994; Harada et al, 1994; Contegiacomo et al, 1995; Lonn et al, 1995) . Amplification data in Champeme et al (1994) , Scorilas et al (1995) and Berns et al (1992) were excluded from estimation of the overall proportion, since they were originally reported in Bieche et al (1994) , Scorilas et al (1993) and Berns et al (1992b) , respectively. Of the 29 reports, 26 determined c-myc amplification by Southern blot, three by slot blot (Tsuda et al, 1989; Zhou et al, 1989; Borg et al, 1992) , and two by polymerase chain reaction (Watson et al, 1993; Lonn et al, 1995) . Two studies utilized more than one method (Zhou et al, 1989; Lonn et al, 1995) .
Seven prognostic factors were analysed for their association with c-myc amplification: lymph node involvement (Escot et al, 1986; Cline et al, 1987; Varley et al, 1987; Adnane et al, 1989; Tavassoli et al, 1989; Berns et al, 1992a; Borg et al, 1992; Kreipe et al, 1993; Nagayama and Watatani, 1993; Scorilas et al, 1993; Champeme et al, 1994; Harada et al, 1994; Lonn et al, 1995) , oestrogen receptor status (Escot et al, 1986; Varley et al, 1987; Adnane et al, 1989; Garcia et al, 1989; Berns et al, 1992b; Borg et al, 1992; Kreipe et al, 1993; Yamashita et al, 1993) , progesterone receptor status (Escot et al, 1986; Adnane et al, 1989; Garcia et al, 1989; Berns et al, 1992b; Borg et al, 1992; Kreipe et al, 1993; Champeme et al, 1994) , age (Escot et al, 1986; Guerin et al, 1988; Adnane et al, 1989; Berns et al, 1992a; Borg et al, 1992; Kreipe et al, 1993) , menopausal status (Varley et al, 1987; Berns et al, 1992a; Borg et al, 1992; Yamashita et al, 1993) , tumour size (Guerin et al, 1988; Adnane et al, 1989; Nagayama and Watatani, 1993; Yamashita et al, 1993) , and tumour grade (Escot et al, 1986; Varley et al, 1987; Adnane et al, 1989; Garcia et al, 1989; Tavassoli et al, 1989; Kreipe et al, 1993) . Data on the HR for death 
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British Journal of Cancer (2000) 83 (12), 1688 -1695 © 2000 or recurrence, as a function of c-myc amplification status, were reported, or could be derived, in six studies (Varley et al, 1987; Tsuda et al, 1989; Berns et al, 1992a; Borg et al, 1992; Yamashita et al, 1993; Lonn et al, 1995) .
Methodologic assessment
The studies were evaluated for the methods, analytic controls, and thresholds utilized to determine the frequency of c-myc amplification (Table 1 ). The primary sources of DNA controls were peripheral blood lymphocytes (PBLs) or normal breast tissue. Studies using PBLs exhibited a somewhat higher frequency of c-myc amplification (24.3%) and lower degree of variability (CV = 18.6%) than those using normal breast tissue (mean = 15.8%, CV = 25.1%), although the difference was not significant, P = 0.180. Most studies used c-mos, β-globin, or β-actin as normal gene controls for amplification. A two-fold increase was the most common amplification threshold, used in 65% of the 23 studies reporting a threshold. Most studies had adequate sample sizes, with 90% studying more than 50 patients, and 62% more than 100. A sample size of 50 gives reasonable precision for estimates of the proportion of c-myc-amplified tumours, with 95% confidence intervals in the range of ± 10-15 percentage points for most of the observed values of prevalence of amplification. The low percentage of small studies suggests that lack of statistical precision is unlikely to be a major source of heterogeneity in this metaanalysis. Only 41% of studies provided a description of the study population that is adequate for deriving clinically useful inferences; many did not indicate the prevalence of metastatic disease or whether treatment was given prior to surgery.
Proportion of c-myc-amplified tumours
The proportion of c-myc-amplified breast tumours ranged from 1-50% (Figure 1) . The estimate of the pooled average frequency of c-myc amplification was (15.7% (95% CI = 12.5-18.8%), based on the weighted average of 26 studies, comprising 3797 patients. However, there was considerable heterogeneity across the studies (χ 2 = 220.89, df = 25, P < 0.001), indicating that the pooled average is an imprecise estimate of the amplification frequency to be expected in any study. Some of the heterogeneity could be due to differences in assay sensitivity and methods. Southern blotting was the only method used in more than three studies, with an overall frequency of 17.0% (95% CI = 13.5-20.5%). Slot blotting and PCR methods demonstrated a lower level of amplification with frequencies of 6.7% (95% CI = 0.1-14.3%) and (11.4% (95% CI = 0.4-22.4%), respectively. The two studies that employed two methods (Tsuda et al, 1989; Watson et al, 1993) , Southern blotting and either slot blotting or PCR, for determining gene amplification indicated that both methods produced frequencies consistent with one another, although the individual values were not provided.
Clinical associations of c-myc amplification
Association of c-myc amplification with known prognostic factors
There was no significant heterogeneity across studies in the association between c-myc and any of the prognostic factors, except for age. Thus, it was valid to pool the estimates across studies for each of the remaining six prognostic factors. Poor histopathological grade, positive lymph node status, and negative progesterone receptor status were each associated with a significantly greater probability of c-myc amplification, while amplification was less likely in tumours from post-menopausal women (Table 2) . Although we combined tumours with histopathological grades I and II in the above analysis, there was a trend toward increasing frequency of c-myc amplification with increasing grade, i.e. 12.5% for grade I, 20.3% for grade II, and 31.4% for grade III tumours. The association between lymph node status and c-myc amplification did not vary according to the threshold used to define amplification (data not shown). Because the association between c-myc and each of the other prognostic factors was evaluated in relatively few studies, the impact of the threshold for amplification could not be assessed.
Association with disease recurrence and overall survival
The pooled estimates indicate that patients with c-myc-amplified tumours are approximately twice as likely as those with a normal level of c-myc to suffer disease recurrence or die (Tables 3A and  3B , respectively). For both disease-free (DFS) and overall survival (OS), there was no significant heterogeneity of HRs across the six studies. Exclusion of the two studies (Yamashita et al, 1993; Lonn et al, 1995) , where HRs were estimated from the P-values, still resulted in approximately two-fold increases in risk. As with the individual prognostic factors, there was relatively little variation in Lonn, 1995 Watson, 1993 PCR methods Borg, 1992 Zhou, 1989 Tsuda, 1989 slot blots Contegiacomo, 1995 Harada, 1994 Yamashita, 1993 Scorilas, 1993 Ottestad, 1993 Nagayama, 1993 Kreipe, 1993 Roux-Dossetto, 1992 Berns, 1992 Munzel, 1991 Meyers, 1990 Brouillet, 1990 Tavassoli, 1989 Garcia, 1989 Adnane, 1989 Guerin, 1988 Bonilla, 1998 Varley, 1987 Cline, 1987 Escot, 1986 Southern blot the threshold used to define c-myc amplification, so its influence on associations with survival could not be assessed.
Publication bias
To evaluate publication bias (i.e. the phenomenon of studies with null results being less likely to be published) we generated a funnel plot of the reported frequency of c-myc amplification in each study plotted against the corresponding sample size (as a surrogate for the precision of the study). It is expected that the amount of scatter around the true mean frequency should decrease as the study sample sizes increase. The presence of publication bias would be indicated by a void in the lower left-hand corner of the funnel plot, suggesting a lack of small published studies presenting a low frequency of amplification (Dickersin et al, 1992) . Although this method is subjective, Figure 2 suggests that a significant publication bias is unlikely in studies of c-myc amplification frequencies of less than 10%, with four of these studies having a sample size ≤ 100, one of which had a sample size of 54 (Figure 2 ).
DISCUSSION
Amplification of c-myc: prevalence in breast cancer
Our results suggest that approximately one in six breast cancers will display amplification of the c-myc gene. Because of the heterogeneity in individual study-specific estimates of c-myc amplification, this estimate may be less precise than suggested by the calculated 95% confidence interval of 12.5-18.8%. Due to the many potential technical and patient-related sources of variability that could not be controlled in our analysis, such heterogeneity is not surprising. Nevertheless, these data indicate that c-myc amplification is likely to occur only slightly less frequently than HER2/neu overexpression, a marker of apparent prognostic relevance in breast cancer. A number of factors may contribute to heterogeneity of results, including tumour sampling variability, assay methodology, and patient populations. The amount and type of tumour material sampled may vary according to the surgical procedure and the size of the tumour. With current diagnostic trends (fortunately) shifting toward smaller tumours, research based on 'convenience' samples may be over-represented by tumours large enough to provide sufficient tissue for genetic analyses. In one study (Borg et al, 1992 ) the analysed samples were noted to be only 10-15% of all breast tumours diagnosed during that period. Sampling artifacts may also be related to the amount and location of normal control tissue taken at surgery, and perhaps, the area within the tumour that was sampled. Previous studies have demonstrated that expression of c-myc varies within the tumour, and that c-myc amplification can be seen in tissue at the leading edge of tumours (Watson et al, 1996) .
Until recently, amplification of the c-myc oncogene has been evaluated by three principal methods: polymerase chain reaction, slot blotting, and Southern blotting, with the latter being the most widely utilized. These differing methodologies may have contributed to the inconsistency of the reported values of c-myc amplification, as they evaluate a mixed population of tumour and non-tumour cells. The future more widespread use of technologies that alleviate this problem, including fluorescence in situ hybridization (FISH), should allow for a more accurate assessment of gene amplification, deletions, and translocations by evaluating gene alteration at the single-cell level. FISH would also provide valuable information about the incidence of amplification in various cell types, particularly in tumour samples that may exhibit genetic heterogeneity. The usefulness of this technique in assessing c-myc genetic alterations has been demonstrated in other cancers, including prostatic and haematopoeitic malignancies (Jenkins et al, 1997) . It will also be of use for future studies to utilize in situ hybridization and immunohistochemistry (IHC), together with FISH, to provide a more comprehensive view of amplification relative to overexpression, particularly since antibodies suitable for IHC are now commercially available. Finally, the patient populations within each study may bias the sample toward higher or lower prevalence of gene amplification, or toward better or worse prognoses. Translating basic research on the biology and function of tumour-associated genes to their evaluation in clinical populations requires attention to aspects of population-based studies that can complicate interpretation of clinical relevance. Details of tumour stage, metastatic prevalence, adjuvant therapy, and average length of patient follow-up were frequently omitted. The time period over which patients were accrued may also be relevant, as it may identify differences in diagnostic or treatment practices.
Amplification of c-myc: role as an independent prognostic factor
Patients with c-myc amplified tumours had an approximate twofold increase in risk of relapse or death. For c-myc to be useful as an independent prognostic factor, it should not be merely a surrogate for one or more established prognostic factors. Although c-myc amplification appears to be somewhat more common in tumours with more aggressive phenotype (Table 2) , it retained its independent prognostic value in the four studies where survival analyses were adjusted for lymph node metastasis, tumour size and/or ER status. Thus, it is likely that c-myc has prognostic value independent of these factors. Adjustment for tumour grade was included in only one of the six survival studies, and this metaanalysis has shown a significant correlation between high tumour grade and c-myc amplification (RR = 1.61, Table 2 ). Thus, we cannot rule out the possibility that the association between c-myc and survival reflects, to some degree, a confounding influence arising from the association between c-myc and grade. However, for this association to be due entirely to confounding by grade would require that the association between amplification and grade be stronger (higher HR) than that observed between amplification and survival. Thus, it is unlikely that grade explains all or most of the association between c-myc and relapse or survival.
Although survival was evaluated in only six studies, the above data suggest that amplified c-myc may have significant value as an independent prognostic factor. Table 3 shows that the magnitude of the pooled HR estimates for DFS and OS are heavily influenced by the large weight (small variance) of Berns et al (1992a) . However, the other five studies have individual HRs that are similar to or larger than this, suggesting that the large weight of the latter contributes toward a more conservative estimate. There is no obvious source of bias that would produce this association with survival as an artifact. Nevertheless, the retrospective nature of the studies requires that this association be viewed as the starting point for more rigorous assessment rather than an established prognostic factor. Additional studies should optimally be embedded in randomized clinical trials to ensure uniform ascertainment and control of confounding factors. Such studies could also allow distinction between prognostic and predictive factors (Hayes et al, 1998) .
Little has been published about the effect of c-myc on treatment response, particularly in breast cancer. New predictive factors are needed, because conventional histopathologic factors do not accurately predict the likelihood that an individual patient will respond to cytotoxic chemotherapy. This is a possible area for future investigation, as some studies have implicated expression of c-myc in resistance to cisplatin-based chemotherapy in multiple tumour types (Walker et al, 1996) , in MDR1 expression in rhabdomyosarcoma cell lines (Prados et al, 1996) , and in resistance to 5-fluorouracil and cisplatin in squamous cell carcinomas of the head and neck (Riva-Lavielle, 1994) . A rigorous study, designed specifically to address the relationship between c-myc amplification and drug and hormone resistance in breast cancer, may provide valuable insight into more effective treatment strategies. Table 3 Study-specific and pooled hazard ratio (HR) estimates of (A) disease-free survival and (B) overall survival in breast cancer patients with c-mycamplified tumours vs non-amplified tumours.
Reference (n)
Hazard 
Amplification of c-myc in relation to other oncogenes
It has been hypothesized that c-myc amplification is a marker for genetic instability, and its permissive effect on downstream gene amplification, or its interaction with co-factor mutations may enhance the likelihood of disease progression to a more aggressive phenotype. A study by Janocko et al (1995) found a preferential sequence for gene amplification in breast cancer, with c-myc most often occurring first, followed by c-erbB-2. Sierra et al (1999) demonstrated in breast cancer patients that Bcl-2 overexpression was strongly associated with lymph node metastasis, but only when c-myc was co-expressed. Caspase 9 is a downstream cofactor in myc-dependent tumourigenesis and progression. Deletion of the gene encoding caspase 9 has been shown to block mycinduced apoptosis and to further promote its oncogenic transformation (Soengas et al, 1999) . These data are also consistent with earlier reports implicating the 1p34-36 chromosomal region, where the caspase 9 gene maps, as a locus of frequent deletion in human tumours Mertens et al, 1997) . These studies provide further support for the examination of co-factor mutations in the context of c-myc amplification as a means of defining the prognostic value of this oncogene.
